苄基硝基胺 | 19091-99-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄基硝基胺
• 英文名称: Benzylnitramin
• 英文别名: benzyl-nitro-amine；ω-Nitramino-toluol；nitrobenzylamine；N-Nitrobenzenemethanamine；N-benzylnitramide
• CAS: 19091-99-7
• 化学式: C₇H₈N₂O₂
• 分子量: 152.153
• InChiKey: FJCCWUVWFDOSAU-UHFFFAOYSA-N

物化性质

• 熔点：
  38-39 °C
• 沸点：
  283.5±33.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苄基硝基胺 、 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 生成 苄基肼
  参考文献：
  名称：

  Thiele, Justus Liebigs Annalen der Chemie, 1910, vol. 376, p. 255

  摘要：

  DOI：
• 作为产物：
  描述：

  N-benzyl-N-nitro-toluene-4-sulfonamide 在 sodium hydroxide 作用下， 生成 苄基硝基胺
  参考文献：
  名称：

  401. nitrourethane的和的烷基化Ñ -nitrotoluene- p磺酰胺

  摘要：

  DOI：

  10.1039/jr9490001883

文献信息

• [EN] DYE COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE<br/>[FR] COMPOSITIONS DE COLORANT, PROCÉDÉS DE PRÉPARATION, CONJUGUÉS ASSOCIÉS, ET PROCÉDÉS D'UTILISATION
  申请人：UNIV CORNELL

  公开号：WO2013109859A1

  公开（公告）日：2013-07-25

  Dye compounds of the formula (1) wherein A is a protective agent group that has a characteristic of modifying the singlet-triplet occupancy of the shown cyanine moiety, and M is a reactive crosslinking group or a group that can be converted to a reactive crosslinking group. Methods for synthesizing the dye compounds and applications for their use are also described.

  化合物的染料的公式（1），其中A是一种保护剂基团，具有修改所示青菁基团的单三态占据特性，而M是一种反应性交联基团或可转化为反应性交联基团的基团。还描述了合成染料化合物的方法以及它们的用途。
• [EN] MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS<br/>[FR] DERIVES DE QUINAZOLINE MACROCYCLIQUE UTILISES COMME AGENTS ANTIPROLIFERATIFS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004105765A1

  公开（公告）日：2004-12-09

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents O, CH2, NH or S; in particular Z represents NH; Y represents -C3-9alkyl-, -C3-9alkenyl-, -C3-9alkynyl-, -C3-7alkyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino or C1-4 alkyloxycarbonylamino-, -C3-7alkenyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino- or C1-4alkyloxycarbonylamino-, C1-5alkyl-oxy-C1-5alkyl-, -C1-5alkyl NR13-, -C1-5alkyl-, -C1-5alkyl-NR14-CO-C1-5alkyl-, -C1-5alkyl-CO NR15-C1-5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-, -C1-3alkyl-NH-CS-Het20-, -C1-3alkyl-NH-CO-Het20-, -C1-2alkyl-CO-Het21-CO-, -Het22-CH2-CO-NH-C1-3alkyl-, -CO-NH-C1-6alkyl-, -NH-CO-C1-6alkyl-, -CO-C1-7alkyl-, -C1-7alkyl-CO-, -C1-6alkyl-CO-C1-6alkyl-, -C1-2alkyl-NH-CO-CR16R17-NH-, -C1-2alkyl-CO-NH-CR18R19-CO-, -C1-2alkyl-CO-NR20-C1-3alkyl-CO-, C1-2alkyl-NR21-CH2-CO-NH-C1-3alkyl-, or -NR22-CO-C1-3alkyl-NH-; X1 represents a direct bond, O or -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR11, -NR11-C1-2alkyl-, CH2-, -O-N=CH- or -C1-2alkyl-; X2 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR12, -NR12-C1-2alkyl-, -CH2-, -O-N=CH- or -C1-2alkyl-. The growth inhibitory effect anti-tumour activity of the present compounds has been demonstrated in vitro, in enzymatic assays on the receptor tyrosine kinase EGFR.

  本发明涉及公式（I）的化合物，其N-氧化物形式，药用可接受的加合物盐及其立体化异构形式，其中Z代表O、CH2、NH或S；特别是Z代表NH；Y代表-C3-9烷基，-C3-9烯基，-C3-9炔基，-C3-7烷基-CO-NH-（可选择地被氨基，单或双（C1-4烷基）氨基或C1-4烷氧羰氨基取代），-C3-7烯基-CO-NH-（可选择地被氨基，单或双（C1-4烷基）氨基或C1-4烷氧羰氨基取代），C1-5烷氧基-C1-5烷基，-C1-5烷基-NR13-，-C1-5烷基，-C1-5烷基-NR14-CO-C1-5烷基，-C1-5烷基-CO NR15-C1-5烷基，-C1-6烷基-CO-NH-，-C1-6烷基-NH-CO-，-C1-3烷基-NH-CS-Het20-，-C1-3烷基-NH-CO-Het20-，-C1-2烷基-CO-Het21-CO-，-Het22-CH2-CO-NH-C1-3烷基-，-CO-NH-C1-6烷基-，-NH-CO-C1-6烷基-，-CO-C1-7烷基-，-C1-7烷基-CO-，-C1-6烷基-CO-C1-6烷基-，-C1-2烷基-NH-CO-CR16R17-NH-，-C1-2烷基-CO-NH-CR18R19-CO-，-C1-2烷基-CO-NR20-C1-3烷基-CO-，C1-2烷基-NR21-CH2-CO-NH-C1-3烷基-，或-NR22-CO-C1-3烷基-NH-；X1代表直接键，O或-O-C1-2烷基-，CO，-CO-C1-2烷基-，NR11，-NR11-C1-2烷基-，CH2-，-O-N=CH-或-C1-2烷基-；X2代表直接键，O，-O-C1-2烷基-，CO，-CO-C1-2烷基-，NR12，-NR12-C1-2烷基-，-CH2-，-O-N=CH-或-C1-2烷基-。本发明化合物的生长抑制效应和抗肿瘤活性已在体外实验中，在EGFR受体酪氨酸激酶的酶促活性测定中得到证明。
• Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants
  申请人：Cabot Corporation

  公开号：US20160075880A1

  公开（公告）日：2016-03-17

  The present invention relates to a modified colorant comprising a colorant having attached at least one organic group. Various embodiments of the organic group are disclosed. For each of these embodiments, preferably the organic group has a defined calcium index value. Also disclosed are various uses for these modified colorants, including inkjet ink compositions.

  本发明涉及一种改性着色剂，其包括至少一个有机基团附着的着色剂。公开了各种有机基团的实施例。对于这些实施例中的每一个，最好是有机基团具有明确定义的钙指数值。还公开了这些改性着色剂的各种用途，包括喷墨墨水组成物。
• [EN] 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM<br/>[FR] DERIVES DE 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE ET DERIVES DE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXYDE ET DE 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE RESPECTIFS, UTILISES COMME MODULATEURS DU RECEPTEUR DE LA 5-HYDROXYTRYPTAMINE (5-HT) POUR LE TRAITEMENT D'AFFECTIONS DU SYSTEME NERVEUX CENTRAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005067933A1

  公开（公告）日：2005-07-28

  The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRaRb)r- or -SO2-, wherein r is from 0 to 2 and each of Ra and Rb is independently hydrogen or alkyl; X is CH or N; R2 is optionally substituted aryl or optionally substituted heteroaryl; preferably R2 is aryl, and more preferably phenyl optionally substituted by one or more trifluoromethyl, halo, cyano, C1-C6 alkyl or C1-C6 alkoxy; A is -NR3- or -O- wherein R3 is: hydrogen; alkyl, acyl, amidoalkyl, hydroxyalkyl or alkoxyalkyl; the other substituents are defined in the claims. The compounds are modulators of the 5-hydroxytryptamine receptor and are useful for the treatment of diseases of the central nervous system such as psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, food uptake disorders, and Huntington’s disease.

  该发明涉及式(I)的取代喹唑啉酮化合物或其药学上可接受的盐，其中Y为C或S；当Y为C时，m为1，当Y为S时，m为2；n为1或2；p为0到3；q为1到3；Z为-(CRaRb)r-或-SO2-，其中r为0到2，Ra和Rb各自独立地为氢或烷基；X为CH或N；R2为可选择地取代的芳基或可选择地取代的杂环烷基；优选R2为芳基，更优选为苯基，可选地取代为一个或多个三氟甲基，卤素，氰基，C1-C6烷基或C1-C6烷氧基；A为-NR3-或-O-，其中R3为：氢；烷基，酰基，酰胺烷基，羟基烷基或烷氧基烷基；其他取代基在权利要求中定义。这些化合物是5-羟色胺受体的调节剂，可用于治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、神经系统疾病、记忆障碍、注意力缺陷障碍、帕金森病、肌萎缩侧索硬化症、阿尔茨海默病、摄食障碍和亨廷顿病。
• [EN] 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY<br/>[FR] DERIVES DE 3-CYANO-QUINOLINE A ACTIVITE ANTIPROLIFERATIVE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005058318A1

  公开（公告）日：2005-06-30

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof. Compounds of formula (I) inhibit tyrosine kinase enzymes.

  本发明涉及式(I)的化合物，其N-氧化物形式，药用可接受的加合盐以及其立体化异构体形式。式(I)的化合物抑制酪氨酸激酶酶。